AU2018308699B2 - Dual mode radiotracer and -therapeutics - Google Patents

Dual mode radiotracer and -therapeutics Download PDF

Info

Publication number
AU2018308699B2
AU2018308699B2 AU2018308699A AU2018308699A AU2018308699B2 AU 2018308699 B2 AU2018308699 B2 AU 2018308699B2 AU 2018308699 A AU2018308699 A AU 2018308699A AU 2018308699 A AU2018308699 A AU 2018308699A AU 2018308699 B2 AU2018308699 B2 AU 2018308699B2
Authority
AU
Australia
Prior art keywords
psma
sifa
compound
imaging
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018308699A
Other languages
English (en)
Other versions
AU2018308699A1 (en
Inventor
Matthias Johannes EIBER
Hans-Jürgen Wester
Alexander Josef WURZER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Klinikum Rechts der Isar der Technischen Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Klinikum Rechts der Isar der Technischen Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen, Klinikum Rechts der Isar der Technischen Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of AU2018308699A1 publication Critical patent/AU2018308699A1/en
Application granted granted Critical
Publication of AU2018308699B2 publication Critical patent/AU2018308699B2/en
Priority to AU2024200440A priority Critical patent/AU2024200440B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
AU2018308699A 2017-07-28 2018-07-30 Dual mode radiotracer and -therapeutics Active AU2018308699B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200440A AU2024200440B2 (en) 2017-07-28 2024-01-24 Dual mode radiotracer and -therapeutics

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
EP17183795.8 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200440A Division AU2024200440B2 (en) 2017-07-28 2024-01-24 Dual mode radiotracer and -therapeutics

Publications (2)

Publication Number Publication Date
AU2018308699A1 AU2018308699A1 (en) 2020-01-23
AU2018308699B2 true AU2018308699B2 (en) 2023-11-30

Family

ID=59501286

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018308699A Active AU2018308699B2 (en) 2017-07-28 2018-07-30 Dual mode radiotracer and -therapeutics
AU2024200440A Active AU2024200440B2 (en) 2017-07-28 2024-01-24 Dual mode radiotracer and -therapeutics

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200440A Active AU2024200440B2 (en) 2017-07-28 2024-01-24 Dual mode radiotracer and -therapeutics

Country Status (20)

Country Link
US (3) US11413360B2 (enExample)
EP (3) EP4000640A1 (enExample)
JP (2) JP7059372B2 (enExample)
KR (2) KR102752620B1 (enExample)
CN (1) CN111132700B (enExample)
AU (2) AU2018308699B2 (enExample)
BR (1) BR112020001785A2 (enExample)
CA (1) CA3071315A1 (enExample)
DK (1) DK3658194T3 (enExample)
EA (1) EA202090370A1 (enExample)
ES (1) ES3011272T3 (enExample)
FI (1) FI3658194T3 (enExample)
HU (1) HUE070098T2 (enExample)
IL (2) IL272291B2 (enExample)
MX (2) MX2020000352A (enExample)
PL (1) PL3658194T3 (enExample)
PT (1) PT3658194T (enExample)
SG (1) SG11202000725WA (enExample)
WO (1) WO2019020831A1 (enExample)
ZA (1) ZA202000467B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3658194T3 (pl) 2017-07-28 2025-09-15 Technische Universität München Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania
KR20210153036A (ko) * 2019-01-30 2021-12-16 테크니쉐 우니베르지테트 뮌헨 암 진단 영상화제들
JP7421232B2 (ja) * 2019-01-30 2024-01-24 テクニシェ ユニバーシタット ミュンヘン フッ化ケイ素アクセプタ置換放射性医薬品とその前駆体
FI3917626T3 (fi) 2019-01-30 2023-08-17 Univ Muenchen Tech Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
CA3191472A1 (en) 2020-09-03 2022-03-10 Curium Us Llc Radiolabeling and formulation for scale up of 64cu-dotatate
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
AU2022219543A1 (en) 2021-02-15 2023-08-17 Technische Universität München Dual mode radiotracer and therapeutics
AU2022273184A1 (en) * 2021-05-14 2023-10-12 Technische Universität München Radiopharmaceutical somatostatin receptor ligands and precursors thereof
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
AU2022323741A1 (en) * 2021-08-05 2024-02-01 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
WO2024023332A1 (en) 2022-07-29 2024-02-01 Technische Universität München Silicon-based fluoride acceptor groups for radiopharmaceuticals
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
EP4631959A3 (en) * 2022-09-20 2025-12-17 Technische Universität München, in Vertretung des Freistaats Bayern Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
CN120417945A (zh) * 2022-11-14 2025-08-01 阿克提斯肿瘤学公司 肾脏中小蛋白滞留的减少
WO2025072791A2 (en) 2023-09-29 2025-04-03 Aktis Oncology, Inc. Miniproteins, conjugates & uses thereof
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
JP2005519861A (ja) * 2001-07-27 2005-07-07 ターゲサム・インコーポレーテッド 治療剤及び撮像剤としての脂質構築物
US10799605B2 (en) * 2014-06-10 2020-10-13 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
JP7266365B2 (ja) * 2015-05-26 2023-04-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 分子および生体分子の18f標識化に有用な新規な複素芳香環フッ化ケイ素アクセプタおよびその調製方法
PL3658194T3 (pl) 2017-07-28 2025-09-15 Technische Universität München Radioznacznik i środki radioterapeutyczne o podwójnym trybie działania
CN116617421A (zh) * 2017-12-11 2023-08-22 慕尼黑工业大学 用于诊断和/或治疗的药物组合物
FI3917626T3 (fi) 2019-01-30 2023-08-17 Univ Muenchen Tech Psma:ta sitova kaksimuotoinen radiomerkkiaine ja terapeuttinen aine
KR20210153036A (ko) 2019-01-30 2021-12-16 테크니쉐 우니베르지테트 뮌헨 암 진단 영상화제들

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S. LITAU ET AL: BIOCONJUGATE CHEMISTRY, vol. 26, no. 12, 16 December 2015 (2015-12-16), pages 2350 - 2359, XP055452403, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00510 *
SIMON LINDNER ET AL: BIOCONJUGATE CHEMISTRY, vol. 25, no. 4, 16 April 2014 (2014-04-16), pages 738 - 749, XP055449461, ISSN: 1043-1802, DOI: 10.1021/bc400588e *
VADIM BERNARD-GAUTHIER ET AL: BIOCONJUGATE CHEMISTRY, vol. 27, no. 2, 17 February 2016 (2016-02-17), pages 267 - 279, XP055305200, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.5b00560 *

Also Published As

Publication number Publication date
AU2024200440A1 (en) 2024-02-08
ZA202000467B (en) 2022-06-29
MX2020000352A (es) 2020-08-17
MX2023007914A (es) 2023-07-13
US11413360B2 (en) 2022-08-16
US20250121102A1 (en) 2025-04-17
SG11202000725WA (en) 2020-02-27
BR112020001785A2 (pt) 2020-09-29
JP2020528461A (ja) 2020-09-24
EA202090370A1 (ru) 2020-05-25
WO2019020831A1 (en) 2019-01-31
US12390540B2 (en) 2025-08-19
JP2022101601A (ja) 2022-07-06
KR102752620B1 (ko) 2025-01-10
EP4424378A3 (en) 2024-12-11
ES3011272T3 (en) 2025-04-07
HUE070098T2 (hu) 2025-05-28
EP4000640A1 (en) 2022-05-25
FI3658194T3 (fi) 2025-02-28
US12453787B2 (en) 2025-10-28
US20200197545A1 (en) 2020-06-25
JP7059372B2 (ja) 2022-04-25
IL272291A (en) 2020-03-31
EP3658194B1 (en) 2024-11-27
CN111132700A (zh) 2020-05-08
IL318092A (en) 2025-02-01
DK3658194T3 (da) 2025-02-17
EP3658194A1 (en) 2020-06-03
CA3071315A1 (en) 2019-01-31
KR20240027896A (ko) 2024-03-04
KR20200064057A (ko) 2020-06-05
AU2024200440B2 (en) 2025-04-24
PL3658194T3 (pl) 2025-09-15
AU2018308699A1 (en) 2020-01-23
IL272291B1 (en) 2025-02-01
CN111132700B (zh) 2022-12-13
PT3658194T (pt) 2025-02-13
US20220370649A1 (en) 2022-11-24
IL272291B2 (en) 2025-06-01
EP4424378A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
AU2024200440B2 (en) Dual mode radiotracer and -therapeutics
JP7549585B2 (ja) がん診断用画像化剤
US20250375544A1 (en) Dual mode radiotracer and -therapeutics
US20230277698A1 (en) Silicon-containing ligand compounds
KR20230160806A (ko) 이중 모드 방사성 트레이서 및 치료법
JP2024517971A (ja) 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
HK40022705B (en) Dual mode radiotracer and -therapeutics
HK40022705A (en) Dual mode radiotracer and -therapeutics
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)